Company profile: RenovoRx
1.1 - Company Overview
Company description
- Provider of targeted delivery solutions for fluids and chemotherapy to selected sites in the peripheral vascular system and tumors. Products include RenovoGem, a gemcitabine-based combination drug-device for locally advanced pancreatic and bile duct cancers delivered via the TAMP (Trans-Arterial Micro-Perfusion) platform; TAMP for targeted chemotherapy delivery; and RenovoCath for isolating blood flow and delivering diagnostic or therapeutics.
Products and services
- RenovoCath: A custom-engineered delivery system that isolates blood flow and delivers diagnostic and therapeutic fluids to selected sites within the peripheral vascular system for targeted administration
- RenovoGem: A therapeutic-grade combination drug-device utilizing gemcitabine to treat locally advanced pancreatic cancer (LAPC) and bile duct cancer, delivered via the TAMP platform for targeted chemotherapy to tumors
- TAMP (Trans-Arterial Micro-Perfusion): A modular therapy platform that targets chemotherapy to tumors to minimize systemic toxicities and improve treatment efficacy through trans-arterial micro-perfusion delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to RenovoRx
Qnovia
HQ: United States
Website
- Description: Provider of medtech and pharmaceutical drug-delivery solutions, including RespiRx, an inhalable prescription nicotine replacement therapy for smoking cessation; an inhaled drug delivery platform that optimizes and tracks dosing to improve efficacy and compliance; and a portable, orientation-agnostic vibrating mesh nebulizer with a digital metered dose interface, Bluetooth-enabled app, and a zero-maintenance disposable cartridge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qnovia company profile →
PLx Pharma
HQ: United States
Website
- Description: Provider of non-steroidal anti-inflammatory drugs for prescription and over-the-counter markets, developing and commercializing these therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PLx Pharma company profile →
Elutia
HQ: United States
Website
- Description: Provider of customized tissue products, including CanGaroo, an acellular envelope for securing implantable electronic devices to promote healthy tissue integration and wound healing; SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction with rapid integration and revascularization and a low inflammatory response; and CanGarooRM, a next-generation drug-eluting biomatrix for securing cardiac devices or neurostimulators.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elutia company profile →
MannKind
HQ: United States
Website
- Description: Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MannKind company profile →
Flowonix Medical
HQ: United States
Website
- Description: Provider of medical device solutions for patients with chronic disorders, featuring the Prometra Programmable Infusion Pump System, an implantable intrathecal drug delivery system indicated for use with specific medications to treat chronic pain and spasticity in adults and adolescents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flowonix Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for RenovoRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to RenovoRx
2.2 - Growth funds investing in similar companies to RenovoRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for RenovoRx
4.2 - Public trading comparable groups for RenovoRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →